From: Abdominal symptoms during Sjogren’s syndrome: a pilot study
SSA+ (n = 80) | SSA- (n = 70) | TOTAL (n = 150) | p-value a | |
---|---|---|---|---|
n (%) | ||||
Male | 3 (3.7) | 6 (8.7) | 9 (6.0) | n.s. |
Age at diagnosis, years | 51.2 (13.4) | 55.0 (11.0) | 53.0 (12.5) | n.s. |
Mean follow-up, years | 10.3 (7.9) | 9.6 (6.9) | 10.0 (7.4) | n.s. |
Salivary gland enlargement | 21 (26.3) | 19 (27.1) | 40 (26.5) | n.s. |
Raynaud’s phenomenon | 29 (36,3) | 18 (25.7) | 47 (31.1) | n.s. |
Articular involvement | 56 (70.0) | 51 (72.9) | 107 (70.9) | n.s. |
Muscular involvement | 32 (40.0) | 35 (50.0) | 67 (44.4) | n.s. |
Neurologic involvement | 15 (18.8) | 19 (27.1) | 34 (22.5) | n.s. |
Cutaneous vasculitis | 9 (11.3) | 1 (1.4) | 10 (6.6) | 0.026 |
Pulmonary involvement | 11 (13.8) | 5 (7.1) | 16 (10.6) | n.s. |
Interstitial nephritis | 6 (7.5) | 2 (2.9) | 8 (5.3) | n.s. |
Fibromyalgia | 2 (2.5) | 10 (7.0) | 12 (8.0) | n.s. |
Depression | 12 (15.0) | 20 (28.6) | 32 (21.3) | 0.0481 |
Hematological involvement | 23 (28.8) | 8 (11.4) | 31 (20.5) | 0.0090 |
Non-Hodgkin lymphoma | 2 (2.5) | 0 | 2 (1.3) | n.s. |
Hypergammaglobulinemia | 35 (43.8) | 2 (2.9) | 37 (24.5) | < 0.0001 |
Positive RF | 12 (15.0) | 2 (2.9) | 14 (9.3) | 0.0115 |
Cryoglobulinemia | 4 (5.0) | 1 (1.4) | 5 (3.3) | n.s. |
Symptomatic treatment of pSS | 67 (83.7) | 58 (84.0) | 126 (84.0) | n.s. |
Specific treatment of pSS | 52 (65.0) | 35 (50.7) | 88 (58.7) | n.s. |
Digestive treatment | 33 (41.2) | 39 (56.5) | 73 (48.7) | n.s. |
mean (sd) | ||||
ESSDAI score | 3.5 (4.9) | 3.2 (4.8) | 3.4 (4.8) | n.s. |
ESSPRI score | 5.5 (2.1) | 6.4 (1.9) | 5.9 (2.1) | 0.0082 |